BCM
AZN icon

Becker Capital Management’s AstraZeneca AZN Stock Holding History

Becker Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.9M Sell
176,914
-4,277
-2% -$825K 1.03% 28
2025
Q4 		$33.3M Sell
181,191
-1,459
-0.8% -$256K 0.95% 30
2025
Q3 		$28M Sell
182,650
-4,024
-2% -$609K 0.82% 40
2025
Q2 		$26.1M Sell
186,674
-3,885
-2% -$544K 0.81% 41
2025
Q1 		$28M Buy
190,559
+1,060
+0.6% +$153K 0.92% 37
2024
Q4 		$24.8M Buy
189,499
+862
+0.5% +$121K 0.81% 44
2024
Q3 		$29.4M Sell
188,637
-1,354
-0.7% -$219K 0.96% 40
2024
Q2 		$29.6M Sell
189,991
-2,581
-1% -$388K 1.02% 32
2024
Q1 		$26.1M Buy
192,572
+1,691
+0.9% +$224K 0.9% 42
2023
Q4 		$25.7M Sell
190,881
-3,309
-2% -$430K 0.93% 38
2023
Q3 		$26.3M Sell
194,190
-3,460
-2% -$473K 1.04% 35
2023
Q2 		$28.3M Sell
197,650
-3,278
-2% -$482K 1.07% 32
2023
Q1 		$27.9M Sell
200,928
-7,613
-4% -$1.02M 1.1% 30
2022
Q4 		$28.3M Sell
208,541
-1,403
-0.7% -$176K 1.32% 27
2022
Q3 		$23M Sell
209,944
-35,143
-14% -$4.46M 1.21% 30
2022
Q2 		$32.4M Sell
245,087
-31,232
-11% -$4.1M 1.56% 17
2022
Q1 		$36.7M Sell
276,319
-15,921
-5% -$1.91M 1.48% 16
2021
Q4 		$34M Sell
292,240
-5,758
-2% -$678K 1.35% 24
2021
Q3 		$35.8M Buy
297,998
+579
+0.2% +$67.4K 1.51% 16
2021
Q2 		$35.6M Sell
297,419
-4,794
-2% -$526K 1.51% 18
2021
Q1 		$30.1M Sell
302,213
-1,426
-0.5% -$143K 1.35% 24
2020
Q4 		$30.4M Sell
303,639
-6,058
-2% -$642K 1.5% 21
2020
Q3 		$33.9M Sell
309,697
-15,329
-5% -$1.7M 1.88% 11
2020
Q2 		$34.4M Sell
325,026
-73,315
-18% -$7.57M 1.95% 10
2020
Q1 		$35.6M Sell
398,341
-157,558
-28% -$14.8M 2.16% 12
2019
Q4 		$55.4M Sell
555,899
-81,913
-13% -$7.71M 1.97% 7
2019
Q3 		$56.9M Sell
637,812
-20,641
-3% -$1.79M 2.17% 6
2019
Q2 		$54.4M Sell
658,453
-3,231
-0.5% -$253K 1.97% 10
2019
Q1 		$53.5M Sell
661,684
-26,310
-4% -$2.07M 1.98% 8
2018
Q4 		$52.3M Sell
687,994
-49,167
-7% -$3.84M 2.04% 9
2018
Q3 		$58.3M Sell
737,161
-23,534
-3% -$1.78M 1.86% 9
2018
Q2 		$53.4M Sell
760,695
-34,121
-4% -$2.45M 1.77% 14
2018
Q1 		$55.6M Buy
794,816
+32,357
+4% +$2.24M 1.84% 15
2017
Q4 		$52.9M Buy
762,459
+12,953
+2% +$873K 1.75% 18
2017
Q3 		$50.8M Buy
749,506
+50,417
+7% +$3.19M 1.74% 15
2017
Q2 		$47.7M Buy
699,089
+5,080
+0.7% +$332K 1.71% 17
2017
Q1 		$43.2M Buy
694,009
+50,765
+8% +$2.96M 1.57% 24
2016
Q4 		$35.1M Buy
643,244
+43,758
+7% +$2.48M 1.3% 37
2016
Q3 		$39.4M Buy
599,486
+8,211
+1% +$537K 1.54% 21
2016
Q2 		$35.7M Buy
+591,275
New +$34.3M 1.46% 30

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Becker Capital Management's AZN Position: Q1 2026 in Review

Becker Capital Management reduced its AstraZeneca (AZN) stake by 2.4% in Q1 2026, selling an estimated $825K and leaving 176,914 shares worth $34.9M. The position accounts for 1.03% of the portfolio, ranked #28.

Becker Capital Management first reported a position in AZN in Q2 2016 and has held it in 40 quarters since. The position peaked at $58.3M in Q3 2018. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Becker Capital Management held 176,914 shares of AstraZeneca worth $34.9M as of Q1 2026.
  • Becker Capital Management sold 4,277 AstraZeneca shares in Q1 2026, an estimated $825K.
  • AstraZeneca made up 1.03% of Becker Capital Management's portfolio in Q1 2026, its #28 holding.
  • Becker Capital Management first reported a position in AstraZeneca in Q2 2016 and has held it in 40 quarters since.
  • Becker Capital Management's AstraZeneca position peaked at $58.3M in Q3 2018.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Becker Capital Management's 13F filing for Q1 2026, filed 11 May 2026.